Maria Pineda, Ph.D.Co-Founder & CEO at Envisagenics
Dr. Maria Luisa Pineda is the co-founder and CEO of Envisagenics, Inc. a biotech spinout of Cold Spring Harbor Laboratory that has developed a machine learning platform to predict disease-causing aberrant splicing through the analysis of massive amounts of RNA-seq data. With this platform, Envisagenics will identify biologically relevant and druggable targets and biomarkers to design therapeutics that will be validated in preclinical and clinical studies.
Dr. Pineda received her PhD from the prestigious Watson School of Biological Sciences at Cold Spring Harbor Laboratory, then she acquired investment experience in technology and life-science startup companies at Canrock Ventures and Golden Seeds, LLC. Under Dr. Pineda’s leadership, Envisagenics has acquired funding from the National Institutes of Health Small Business Innovation Research (SBIR) program and pre-seed investments from Topspin Partners and the Long Island Emerging Technology Fund, and from Breakout Labs, a Peter Thiel foundation. Envisagenics also closed a $2.35M seed round backed by Third Kind Venture Capital (3KVC), Cosine, LLC (NYC biotech investors), Dolby Family Ventures, Dynamk Capital, NY Empire State Development (ESD), and SV Angel. Most recently, Envisagenics was selected as a winner of JLABS Artificial Intelligence for Drug Discovery QuickFire Challenge, and was awarded with a cash prize as well as a bench and desk space for one year at JLABS@NYC. Envisagenics was also named the North American Winner of the Innovate.AI competition, winning a $1M Investment from M12 and Madrona Venture Group, as well as Microsoft Azure credits. Dr. Pineda has been named one of the top 20 Latinas in NYC by El Diario, NYC’s oldest Spanish Language newspaper and was selected for the Stanford Latino Entrepreneur Leaders Program developed by the Latino Business Action Network and the Stanford Graduate School of Business.